BIRKENFELD (dpa-AFX) - Stratec Biomedical Systems AG (SBSG) reported Thursday that its consolidated net income for the first half, excluding certain items, amounted to 10.31 million euros, 5.8 percent higher than last year's 9.81 million euros. Earnings per share were 0.87 euro, up 4.8 percent from 0.83 euro last year.
Six-month earnings before interest and tax or EBIT rose 5.3 percent to 12.62 million euros. The EBIT margin for the first half of 2016 came to 16.2 percent, down 95 basis points from 17.1 percent a year ago.
Half-year sales grew 11.5 percent to 78.0 million euros from 70.01 million euros a year ago. Organic second-quarter sales, excluding sales at acquired companies, grew year-on-year by 2.5 percent to 36.3 million euros.
Looking ahead, for the 2016 financial year as a whole, STRATEC expects its sales - following the time-apportioned consolidation of Diatron and STRATEC Consumables - to increase to between 175 million euros and 182 million euros. EBIT margin, excluding acquisition and integration expenses, would be 16.0 percent to 17.5 percent.
In the 2017 financial year, the two companies acquired will be consolidated in the STRATEC Group for the first time for a full reporting period. Excluding further acquisitions, sales are expected to rise to between 205 million euros and 220 million euros, with a slight increase in the EBIT margin compared with 2016.
In Germany, the shares are currently trading at 52.50 euros, up 1.92 percent.
Copyright RTT News/dpa-AFX